biostudies-literatureNilsson JSwedish Federal GovernmentSkåne University HospitalEivind och Elsa K:son Sylvan StiftelseJoint Programme-Neurodegenerative Disease ResearchSwedish Research CouncilAlzheimer Drug Discovery FoundationSwedish Brain FoundationGE HealthcareUniversity College London Hospitals Biomedical Research CentreStiftelsen för Gamla TjänarinnorMedical Research CouncilErling-Persson Family FoundationHjärnfondenHorizon 2020Swedish GovernmentNational Institute for Health and Care ResearchAlzheimer's AssociationAlzheimerfonden2414-2427https://www.ebi.ac.uk/biostudies/studies/S-EPMC11224614biostudies-literatureUnknown147(7)Synaptic dysfunction and degeneration is likely the key pathophysiology for the progression of cognitive decline in various dementia disorders. Synaptic status can be monitored by measuring synaptic proteins in CSF. In this study, both known and new synaptic proteins were investigated and compared as potential biomarkers of synaptic dysfunction, particularly in the context of Alzheimer's disease (AD). Seventeen synaptic proteins were quantified in CSF using two different targeted mass spectrometry assays in the prospective Swedish BioFINDER-2 study. The study included 958 individuals, characterized as having mild cognitive impairment (MCI, n = 205), AD dementia (n = 149) and a spectrum of other neurodegenerative diseases (n = 171), in addition to cognitively unimpaired individuals (CU, n =Brain : a journal of neurologyCerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.PMC112246142020-O0000282022-01018UKDRI-1003AF-980907FO2022-0204Palmqvist SJanelidze SNilsson JHansson OZetterberg HPichet Binette ASpotorno NBrinkmalm AStomrud EAshton NJBrum WSBlennow KGobom JfalseCerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.Synaptic dysfunction and degeneration is likely the key pathophysiology for the progression of cognitive decline in various dementia disorders. Synaptic status can be monitored by measuring synaptic proteins in CSF. In this study, both known and new synaptic proteins were investigated and compared as potential biomarkers of synaptic dysfunction, particularly in the context of Alzheimer's disease (AD). Seventeen synaptic proteins were quantified in CSF using two different targeted mass spectrometry assays in the prospective Swedish BioFINDER-2 study. The study included 958 individuals, characterized as having mild cognitive impairment (MCI, n = 205), AD dementia (n = 149) and a spectrum of other neurodegenerative diseases (n = 171), in addition to cognitively unimpaired individuals (CU, n =2024-01-01T00:00:00Z2024 Jul2026-06-03T21:55:43.434Z2025-04-04T19:23:27.025ZS-EPMC112246143832533110.1093/brain/awae032